These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 6455013)

  • 1. The evaluation of thromboembolic diseases: what to do now that the radioimmunoassay has arrived.
    Handin RI
    West J Med; 1981 Jul; 135(1):50-1. PubMed ID: 6455013
    [No Abstract]   [Full Text] [Related]  

  • 2. Platelet markers of thromboembolic disease.
    Wohl H
    West J Med; 1981 Jul; 135(1):19-24. PubMed ID: 6167074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Laboratory application of radioimmunoassay in the quantitation of molecular markers of hemostatic activation.
    Walenga JM; Fareed J; Hoppensteadt D
    Semin Thromb Hemost; 1984 Oct; 10(4):294-305. PubMed ID: 6240117
    [No Abstract]   [Full Text] [Related]  

  • 4. [Plasma beta-thromboglobulin level in thromboembolic diseases: a marker of in-vivo platelet release reaction].
    Modiano A
    G Clin Med; 1980 Sep; 61(9):672-8. PubMed ID: 6162700
    [No Abstract]   [Full Text] [Related]  

  • 5. [Clinical usefulness of the measurement of plasma platelet release factors in surgical patients with cardiovascular diseases].
    Kawada T; Funaki S; Arase K; Hozon M; Masaki H
    Rinsho Kyobu Geka; 1984 Jul; 4(4):455-62. PubMed ID: 6209773
    [No Abstract]   [Full Text] [Related]  

  • 6. The application of polyethylene glycol to radioimmunoassays used in haemostasis.
    Woodhams BJ; Kernoff PB
    Thromb Res; 1983 Feb; 29(3):333-41. PubMed ID: 6189241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Usefulness of several laboratory tests on prethrombotic status in arterial vascular pathology].
    Arosio E; Lechi C; Pancera P
    Recenti Prog Med; 1989 Jan; 80(1):18-24. PubMed ID: 2523551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thrombin and plasmin activity and platelet activation in the development of venous thrombosis.
    Owen J; Kvam D; Nossel HL; Kaplan KL; Kernoff PB
    Blood; 1983 Mar; 61(3):476-82. PubMed ID: 6218846
    [No Abstract]   [Full Text] [Related]  

  • 9. Radioimmunoassay of beta-thromboglobulin.
    Kaplan KL; Owen J
    Methods Enzymol; 1982; 84():93-102. PubMed ID: 6178941
    [No Abstract]   [Full Text] [Related]  

  • 10. [Clinical tests on the diagnosis of thrombosis].
    Yamanaka M
    Nihon Rinsho; 1986 May; 44(5):1076-80. PubMed ID: 2943914
    [No Abstract]   [Full Text] [Related]  

  • 11. [Platelet factor 4 and beta-thromboglobulin].
    Taki M; Yamada K
    Rinsho Byori; 1987 Jun; Spec No 71():192-7. PubMed ID: 2957528
    [No Abstract]   [Full Text] [Related]  

  • 12. Beta-thromboglobulin (beta tg) and platelet factor 4 (PF4) in patients with myeloproliferative diseases.
    Fabris F; Luzzatto G; Randi ML; Cella G
    Thromb Haemost; 1994 Sep; 72(3):484-6. PubMed ID: 7710537
    [No Abstract]   [Full Text] [Related]  

  • 13. Relative sensitivity to double thawing of plasma samples for some tests used in thrombosis research.
    De Caterina R; Gazzetti P; Michelassi C; D'Ascanio A; Bombardieri S
    Thromb Res; 1988 Jan; 49(1):123-7. PubMed ID: 2964741
    [No Abstract]   [Full Text] [Related]  

  • 14. Beta-thromboglobulin and platelet factor 4 in juvenile myocardial infarction.
    Caimi G; Hoffmann E; Montana M; Incalcaterra E; Canino B; Lo Presti R
    Clin Appl Thromb Hemost; 2007 Jan; 13(1):108-9. PubMed ID: 17164501
    [No Abstract]   [Full Text] [Related]  

  • 15. Markers of thrombotic activity in arterial disease.
    Donaldson MC; Matthews ET; Hadjimichael J; Rickles FR
    Arch Surg; 1987 Aug; 122(8):897-900. PubMed ID: 2957982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical evaluation of hemostatic molecular markers.
    Kazama M
    Nihon Ketsueki Gakkai Zasshi; 1988 Dec; 51(8):1387-94. PubMed ID: 2854693
    [No Abstract]   [Full Text] [Related]  

  • 17. Accumulation of risk factors enhances the prothrombotic state in atrial fibrillation.
    Ohara K; Inoue H; Nozawa T; Hirai T; Iwasa A; Okumura K; Lee JD; Shimizu A; Hayano M; Yano K
    Int J Cardiol; 2008 Jun; 126(3):316-21. PubMed ID: 17689760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Evaluation of thrombotic risk in type 2 diabetes: determination of platelet factor 4 and beta thromboglobulin].
    Diop S; Ka-Cisse M; Toure-Fall AO; Diagne Fall-Sarr F; Diop SN; Thiam D; Diakhate L
    Dakar Med; 2002; 47(2):247-51. PubMed ID: 15776686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Measurement of beta-thromboglobulin and platelet factor 4 to follow up patients with artificial heart valves.
    Bellon JL; Castellanos C; Acevedo L; Amiral J
    Semin Thromb Hemost; 1993; 19 Suppl 1():178-82. PubMed ID: 8362264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. D-dimer level influences thromboembolic events in patients with atrial fibrillation.
    Nozawa T; Inoue H; Hirai T; Iwasa A; Okumura K; Lee JD; Shimizu A; Hayano M; Yano K
    Int J Cardiol; 2006 Apr; 109(1):59-65. PubMed ID: 15992948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.